You cannot place a Cefoxitin disk directly onto a primary clinical… — Medical Notes Dr. Ayman Radwan — TG.ME

You cannot place a Cefoxitin disk directly onto a primary clinical specimen (like raw pus, tissue biopsies, or ear drainage). The assay requires isolating a pure bacterial colony from a mature culture, standardizing its turbidity, and incubating it for an additional 18–24 hours. Consequently, it will always follow the culture timeline as a retrospective confirmatory step, meaning it cannot provide the rapid, immediate de-escalation answers needed on Day 1 or Day 2 of a severe infection ... Can the automated MIC panel report MSSA/MRSA and the Cefoxitin disk show the opposite? Yes. True phenotypic mismatches occur due to distinct molecular profiles (a)Automated Panel says Resistant / Cefoxitin Disk says Susceptible: This is typical of BORSA (Borderline Oxacillin-Resistant S. aureus). These strains lack the mecA gene entirely but hyper-produce native PC1 beta-lactamases. Because they lack mecA , Cefoxitin successfully saturates and shuts down their native targets, killing them cleanly on the disk assay despite an elevated automated oxacillin MIC (b) Automated Panel says Susceptible / Cefoxitin Disk says Resistant: This occurs in highly repressed h-MRSA isolates. Automated testing micro-wells can miss low-frequency resistant subpopulations due to low inoculum densities and rapid read times. The Cefoxitin disk exerts sustained, heavy selection pressure over 24 hours, completely unmasking the hidden, PBP2a-reliant resistant subpopulation. طيب ليه الدكاترة مبتعملش الفحص ده؟ The Clinical Tie-Breaker: If these laboratory methods clash, or if an automated panel reads "Susceptible" but the patient is actively failing therapy, clinicians disregard the automated report and treat as MRSA. The laboratory resolves the conflict by deploying a definitive molecular assay to identify the physical presence of the resistance gene. ................... Where resources permit, the absolute standard for MRSA confirmation remains the rapid molecular multiplex panel (such as BioFire BCID or GeneXpert) with is deployed directly on a positive sample, it detects the ( oriC) (staphylococcal specific gene), nuc or coA (confirming S. aureus), and mecA/C (confirming resistance) simultaneously within 1 hour